ArticleAnnals of hematology2022

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.

Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.